Cargando…

Research progress on criteria for discontinuation of EGFR inhibitor therapy

The clinical success of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) as therapeutic agents has prompted great interest in their further development and clinical testing for a wide variety of malignancies. However, most studies have focused on the efficacy of TKI, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhuang, Hong-qing, Yuan, Zhi-yong, Wang, Jun, Wang, Ping, Zhao, Lu-jun, Zhang, Bai-lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3475392/
https://www.ncbi.nlm.nih.gov/pubmed/23082072
http://dx.doi.org/10.2147/OTT.S36103